Exelixis | EXEL - Trade Debtors


Exelixis reported $328.95M in Trade Debtors for its fiscal quarter ending in March of 2026.





Trade Debtors Change Date
Acadia Pharmaceuticals USD 166.33M 17.95M Jun/2026
Agios Pharmaceuticals USD 16.13M 5.56M Mar/2026
Akebia Therapeutics USD 47.03M 19.19M Dec/2025
Amgen USD 10.23B 1.09B Jun/2026
AstraZeneca USD 18.86B 972M Jun/2026
Bayer EUR 18.55B 4.36B Mar/2026
BioMarin Pharmaceutical USD 1.06B 157.13M Jun/2026
Bristol-Myers Squibb USD 13.83B 535M Jun/2026
Cytokinetics USD 6.83M 10.94M Mar/2026
Eisai JPY 253.13B 26.12B Jun/2026
Eli Lilly USD 23.48B 2.3B Jun/2026
Exelixis USD 328.95M 42.03M Mar/2026
Genmab DKK 1.22B 192M Jun/2026
Glaxosmithkline GBP 10.49B 40.6M Mar/2026
Incyte USD 1.13B 73.7M Jun/2026
Ionis Pharmaceuticals USD 58.84M 15.16M Jun/2026
MacroGenics USD 10.42M 2.95M Mar/2026
Merck USD 12.21B 435M Mar/2026
Moderna USD 17M 54M Jun/2026
Nektar Therapeutics USD 3.6M 1.82M Mar/2026
Neurocrine Biosciences USD 887M 118.9M Jun/2026
Novartis USD 9.85B 252M Jun/2026
Pfizer USD 16.19B 19M Jun/2026
Puma Biotechnology USD 28.1M 3.52M Jun/2024
Sanofi EUR 482M 85M Mar/2026
Takeda JPY 956.14B 79.79B Jun/2026
Ultragenyx Pharmaceutical USD 60M 98M Mar/2026
Xencor USD 42.23M 30.23M Jun/2026